Where I see patients (2)
Selected research
-
HLH-like syndromes associate with increased risk of death and CD19- relapse after CAR T in pediatric B-ALL.
Blood advances
-
Ribonucleotide Reductase Inhibition Overcomes FLT3 Inhibitor Resistance in Acute Myeloid Leukemia.
bioRxiv : the preprint server for biology
-
Therapeutic Targeting of IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.
Blood
Clinical trials
Venetoclax Basket Trial for High Risk Hematologic Malignancies
To determine the maximum tolerated dose (MTD of venetoclax given in combination with regimen-prescribed chemotherapy. The MTD is defined as the dose level associated with observed DLTs in <33% of enrolled subjects
Recruiting
More about this studyA Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Mye...
The incidence of dose limiting toxicities (DLTs) after the 1st course of therapy will be measured at different dose levels.
Recruiting
More about this studyContact me
Tender wagging care
Our therapy dogs spread joy and smiles at the bedside and throughout the hospital.
Visit Child Life services
